Carisma Therapeutics Stock Total Asset
| CARM Stock | 0.85 0.01 1.19% |
Carisma Therapeutics fundamentals help investors to digest information that contributes to Carisma Therapeutics' financial success or failures. It also enables traders to predict the movement of Carisma Stock. The fundamental analysis module provides a way to measure Carisma Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Carisma Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 89.6 M | 65.7 M | |
| Intangibles To Total Assets | (1.31) | (1.25) |
Carisma | Total Asset |
Carisma Therapeutics Company Total Asset Analysis
Carisma Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Carisma Therapeutics Total Asset | 89.55 M |
Most of Carisma Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carisma Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Carisma Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Carisma Therapeutics is extremely important. It helps to project a fair market value of Carisma Stock properly, considering its historical fundamentals such as Total Asset. Since Carisma Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Carisma Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Carisma Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Carisma Total Asset Historical Pattern
Today, most investors in Carisma Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Carisma Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Carisma Therapeutics total asset as a starting point in their analysis.
Carisma Therapeutics Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Carisma Total Assets
Total Assets |
|
Based on the latest financial disclosure, Carisma Therapeutics has a Total Asset of 89.55 M. This is 98.81% lower than that of the Biotechnology sector and 95.47% lower than that of the Health Care industry. The total asset for all United States stocks is 99.7% higher than that of the company.
Carisma Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Carisma Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Carisma Therapeutics could also be used in its relative valuation, which is a method of valuing Carisma Therapeutics by comparing valuation metrics of similar companies.Carisma Therapeutics is currently under evaluation in total asset category among its peers.
Carisma Fundamentals
| Return On Equity | -3.63 | ||||
| Return On Asset | -0.56 | ||||
| Operating Margin | (3.88) % | ||||
| Current Valuation | 12.1 M | ||||
| Shares Outstanding | 41.75 M | ||||
| Shares Owned By Insiders | 28.53 % | ||||
| Shares Owned By Institutions | 31.51 % | ||||
| Number Of Shares Shorted | 558.58 K | ||||
| Price To Book | 114.10 X | ||||
| Price To Sales | 1.76 X | ||||
| Revenue | 14.92 M | ||||
| EBITDA | (85.89 M) | ||||
| Net Income | (86.88 M) | ||||
| Total Debt | 3.12 M | ||||
| Book Value Per Share | (0.27) X | ||||
| Cash Flow From Operations | (81.18 M) | ||||
| Short Ratio | 3.11 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Target Price | 9.8 | ||||
| Number Of Employees | 107 | ||||
| Market Capitalization | 35.65 M | ||||
| Total Asset | 89.55 M | ||||
| Retained Earnings | (245.1 M) | ||||
| Working Capital | 64.56 M | ||||
| Net Asset | 89.55 M |
About Carisma Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carisma Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carisma Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carisma Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Carisma Therapeutics Piotroski F Score and Carisma Therapeutics Altman Z Score analysis. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.